Nuvation Bio
NUVBPhase 3Nuvation Bio is a publicly traded, commercial-stage oncology company with a mission to develop new generations of cancer medicines that address drug resistance and limited efficacy of current therapies. Founded by Dr. David Hung, the architect behind blockbuster prostate cancer drug XTANDI, the company leverages a patient-first mindset and a deep pipeline of novel therapeutic candidates targeting critical cancer pathways. With offices in New York, San Francisco, Boston, and Shanghai, Nuvation Bio is positioned to tackle some of the toughest challenges in cancer treatment.
NUVB · Stock Price
Historical price data
AI Company Overview
Nuvation Bio is a publicly traded, commercial-stage oncology company with a mission to develop new generations of cancer medicines that address drug resistance and limited efficacy of current therapies. Founded by Dr. David Hung, the architect behind blockbuster prostate cancer drug XTANDI, the company leverages a patient-first mindset and a deep pipeline of novel therapeutic candidates targeting critical cancer pathways. With offices in New York, San Francisco, Boston, and Shanghai, Nuvation Bio is positioned to tackle some of the toughest challenges in cancer treatment.
Technology Platform
Focuses on developing a deep pipeline of differentiated and novel therapeutic candidates targeting critical pathways cancer cells use to grow, generated from proprietary discovery programs and business development.
Pipeline
17| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Taletrectinib + Crizotinib | Non Small Cell Lung Cancer | Phase 3 | |
| safusidenib + Placebo | Glioma | Phase 3 | |
| Taletrectinib + Placebo | Non-small Cell Lung Cancer (NSCLC) | Phase 3 | |
| AB-106 | Solid Tumor | Phase 2 | |
| Taletrectinib | Non Small Cell Lung Cancer | Phase 2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Competes in the highly competitive oncology space against large pharma and other biotechs. Key differentiation is the proven track record of founder David Hung in rapidly developing blockbuster cancer drugs (XTANDI) and a focused strategy on the most difficult-to-treat cancers where current therapies fail.